The Antiplatelet Drugs Segment
While anticoagulants, particularly NOACs, are a major force in the Blood thinning Drugs Market, the antiplatelet drugs segment is also significant. Antiplatelet drugs, such as aspirin and clopidogrel, work by preventing platelets from clumping together to form clots. They are a cornerstone of treatment for conditions like coronary heart disease and for preventing strokes in patients with a history of a heart attack.
The market for antiplatelet drugs is well-established, with a wide range of generic and branded options available. While the growth of this segment may not be as explosive as that of NOACs, its role in the prevention of arterial thrombosis is critical and ensures its continued relevance in the market.